Skip to content
Disclosery

Versant Venture Management, LLC

Follow

13F filer, CIK 1560009, San Francisco, CA

Versant Venture Management, LLC reported $86,748,024 across 7 holdings for the quarter ended 2024-12-31, in a 13F-HR filed 2025-02-12.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000950123-25-001612

Period
2024-12-31
Reported value
$86.7M
Holdings
7
Top 10 weight
100%
New
2
Sold out
1

Largest buys vs the previous quarter

SecurityShares changeApprox. value
GLUEnew+5,652,922$39.2M
Tempest Therapeutics, Inc.new+3,507,055$2.93M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
GRITSTONE BIO INCexited-3,561,150-$2.07M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q4 2024

Share positions as resolved from 13F-HR 0000950123-25-001612, largest first. % of portfolio is the value over $86,748,024, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
GLUEMONTE ROSA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 5,652,922 shares 5,652,922$39.2M45.22%newTimeline
CRSPCRISPR THERAPEUTICS AGQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 498,558 shares; 2024Q4: 498,558 shares 498,558$19.6M22.62%0Timeline
CTNMCONTINEUM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 918,163 shares; 2024Q4: 918,163 shares 918,163$13.5M15.51%0Timeline
SKYESKYE BIOSCIENCE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,007,704 shares; 2024Q4: 2,007,704 shares 2,007,704$5.68M6.55%0Timeline
REPARE THERAPEUTICS INCREPARE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,646,657 shares; 2024Q4: 2,646,657 shares 2,646,657$3.47M4%0
Tempest Therapeutics, Inc.Tempest Therapeutics, Inc.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 3,507,055 shares 3,507,055$2.93M3.37%new
Adverum Biotechnologies, In…Adverum Biotechnologies, Inc.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 506,821 shares; 2024Q4: 506,821 shares 506,821$2.37M2.73%0

Sold out in Q4 2024

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
GRITSTONE BIO INCGRITSTONE BIO INC3,561,150$2.07Mshares

How Q4 2024 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000950123-25-001612 base2025-02-12acceptance time not in the bulk data set